The outcome in children with acute leukaemia with (n=90) and without Down's syndrome (n=4377) was compared. Sixty three (70%) of those with Down's syndrome had acute lymphoblastic leukaemia and in comparison with 3664 (84%) controls had similar prognostic features except for a significant excess of the 'common' immunological subtype of acute lymphoblastic leukaemia. The outcome of the children with Down's syndrome was significantly worse with a five year overall actuarial survival of 28% compared with 59% in the control group. It appeared that both suboptimal chemotherapy and a high rate of infective problems contributed to the poor survival. Twenty six children with Down's syndrome had acute myeloblastic leukaemia and were significantly younger and had a higher percentage of the megakaryocytic and erythroid subtypes of acute myeloblastic leukaemia than the 713 controls. The outcome was similar in the two groups.
The first reported case of the occurrence of Down's syndrome and acute leukaemia was made in an infant in 1930.1 It was over 30 years later before Krivit and Good, in a nationwide American survey, found more than a casual association between these two conditions.2 Further studies showed that children with Down's syndrome had a 15-30 fold increased incidence of leukaemia.3 ' The life expectancy of children with Down's syndrome has increased with more effective treatment of respiratory infections and congenital heart disease. In a recent cohort from Canada 81-9% who had no major congenital heart disease were still alive at 20 years, though substantially fewer of those with congenital heart disease survived. 5 There has thus been an increase in the proportion of children with Down's syndrome surviving to develop leukaemia. This factor coupled with the concept that these children should be treated as normal children and be given every opportunity of cure for any life threatening disease has increased the numbers being referred to specialist paediatric oncology and haematology centres. With this in mind the aim of the study was to investigate the present outcome of children with Down's syndrome and acute leukaemia.
Patients and methods
The National Registry of Childhood Tumours at the Childhood Cancer Research Group (CCRG) , with ascertainment based on the national cancer registration scheme, includes the great majority of children aged under 15 years with malignant disease in Great Britain. 6 The United Kingdom Children's Cancer Study Group (UKCCSG) has a register of patients treated by its members throughout the United Kingdom and the Irish Republic and a copy of this register is also kept at the CCRG. The files of both registers were searched for children with Down's syndrome and acute leukaemia diagnosed between 1971 and 1986, and those patients treated by members of the UKCCSG at 17 centres were identified. Permission was requested to use these patients in the study. Questionnaires were completed either by one of the authors (GAL, 40%) or by members of the UKCCSG. Information gathered included congenital abnormalities, clinical features, pretreatment investigations (including chromosome analysis), treatment, and outcome. Follow up continued until October 1988.
Ninety eight children were identified with Down's syndrome and acute leukaemia. Eight patients were excluded from the study: one child was more than 15 years of age at diagnosis and the remainder were incorrectly diagnosed or had insufficient information available. Ninety children were thus included in the study, of whom 63 (70%) had acute lymphoblastic leukaemia, 26 (29%) had acute myeloblastic leukaemia, and one patient had unspecified leukaemia. This distribution is similar to the incidence reported by Rosner and Lee in 1972.7 This represents 68% of the patients on the National Registry with Down's syndrome and acute leukaemia diagnosed and treated in mainland Britain. The 90 children with Down's syndrome in the study were compared with 4377 children without Down's syndrome with acute leukaemia who were ascertained from the National Registry, and treated by UKCCSG members, who were diagnosed between 1971 and 1986.
Patient characteristics and survival of the two groups were analysed using standard statistical methods. Survival rates were also compared for children with Down's syndrome receiving different intensity treatment. Differences between survival curves were analysed using log rank tests.8
Results

CLINICAL FEATURES
The presenting features of the 63 children with and 3664 children without Down's syndrome who had acute lymphoblastic leukaemia are shown in table 1. There was no difference between the groups in sex, age, or presenting white cell count. There was a significantly higher proportion of the common immunological phenotype of acute lymphoblastic leukaemia in the group with Down's syndrome (X2=4-03 on 1 df, p<005), and a corresponding deficit of T cell acute lymphoblastic leukaemia.
Children with Down's syndrome were classified by mode of treatment. Group 0 (five patients) received no treatment because either the patient died before treatment started (one patient) or a positive decision was made not to treat (four patients); two of these children had ventricular septal defects with pulmonary hypertension.
Group I (19 patients) received one or two drug induction, and 64% of the patients available for central nervous system directed treatment received it. Group II (39 patients) received (more intensive treatment and 34 (87%) received central nervous system directed treatment. Only nine of these patients were not included in United Kingdom acute lymphoblastic leukaemia (UKALL) trials, eight (21%) were treated on the UKALL X protocol, although many patients did not adhere strictly to the protocol.
Prognostic factors in the treatment groups were compared and there was no significant difference (table 2) .
The presenting features of 26 children with Down's syndrome and acute myeloblastic leukaemia were similarly compared with 713 children with acute myeloblastic leukaemia but without Down's syndrome ( (fig 2) . There was a significant difference in the relapse free survival between the two groups (p<0-01). In group II six children had central nervous system relapses and two are long term survivors 13 years and eight years from diagnosis, although the latter child is still on continuous treatment four years from relapse. A third child remains on treatment because of recent bone marrow and central nervous system relapse. Two patients had a central nervous system relapse in group I, one patient from group I and one from group II Non-Down's syndrome (n=3587) A substantial proportion of patients died from infection: four patients (21%) in group I and 11 children (28%) from group II. Four of the group II patients died during induction and one during an intensification module. The remaining infections occurred in remission during continuing treatment. In addition one child in group II died of infection but was found to have relapsed at postmortem examination. Deaths occurred at a wide range of ages between 17 months and 14 years. There was a variety of causative organisms. Six patients died due to unidentified pathogens causing septicaemia or pneumonia. In group I, two patients died of bacterial septicaemia: one from viral hepatitis and the other from varicella pneumonitis. In group II, most died due to presumed bacterial infections but one patient died from mycoplasma pneumonia, one from Pneumocystis carinii pneumonia, and a further patient died from a combination of measles and P carinii pneumonia (table 6) . Two children died as a consequence of their congenital heart disease associated with pneumonia while on continuous treatment.
The analysis of deaths from infection showed no significant difference between the two treatment groups. The five year mortality rate conditional on not having died of their leukaemia was 47% in group I and 37% in group II. The deaths in group II tended to occur earlier; the mortality rate during the first year from diagnosis was 28% in group II compared with only 5% in group I. Acute myeloblastic leukaemia The five year overall survival rate was 19% (95% confidence interval 15-3 to 23 3) for those without Down's syndrome and 14% for those with Down's syndrome and acute myeloblastic leukaemia (the confidence interval could not be calculated because there were insufficient survivors). There were no survivors among the seven children in group I; at best, only partial remission was obtained and the last child died of relapse while on treatment. Three children have survived in group II with an event free survival of 27% with follow up of 33 months to six years. One child was a non-responder with chronic heart failure; two children relapsed on treatment and one off treatment. There were five treatment related deaths. Two children died of infection during induction and one child of fungal pneumonia on continuous treatment. Two children, both off treatment, died due to cardiomyopathy presumably due to daunorubicin; one child had been retreated for a bone marrow relapse. One patient had a known atrial septal defect but the other had a normal echocardiogram at diagnosis.
Discussion
The children with Down's syndrome in this series have very poor survival rates. Those with acute lymphoblastic leukaemia had a very much lower overall survival rate (28% at five years) than those without (59%). The poor survival occurred despite the prognostic factors, age, and presenting white cell count being similar, and a higher proportion of the children with Down's syndrome and acute lymphoblastic leukaemia had the common acute lymphoblastic leukaemia immunological phenotype. The similarity in the responsiveness of disease is also borne out by the fact that 97% of children in group II achieved remission, excluding two children who died of infection before remission could be confirmed. This result is very similar to that found in the study of Miller et al using vincristine, prednisolone, and crisantaspase (asparaginase) as induction drugs. 9 This study does highlight a number of reasons for the survival difference. The treatment regimens used are obviously very important. In the minimal treatment group, only 79% achieved remission and there were no event free survivors. Tolerance of the continuous treatment was poor in children with Down's syndrome and many reports were received commenting on decreased compliance owing to mucositis, myelosuppression, and infection. Robison et al, in their 10 year survey comparing children with acute lymphoblastic leukaemia and without Down's syndrome, found the five year overall survival lower in the group with Down's syndrome (50% compared with 65%). ' Induction failure was higher in the children with Down's syndrome (19% compared with 6%), but the relapse free survival was not significantly different.
One of the main causes of mortality in children with Down's syndrome but without leukaemia is infection, so the fact that many of these children with acute lymphoblastic leukaemia succumb to overwhelming infection is not surprising, although it is a worrying feature in their treatment. Induction deaths owing to infection occurred in 5% of group I and 13% in group II. The high incidence continued during maintenance with a further eight children dying in group II. These figures contrast with the incidence of 0 5% in an analysis of 184 children at the Hospital for Sick Children, London, undergoing induction treatment for acute lymphoblastic leukaemia. 14 A further study from the same centre in 1981 showed 8% of children died from infection while on continuous treatment.'5 Most deaths occurred in children under 5 years and as many as 16% were thought to be due to measles. In the group with Down's syndrome, 24% died of infection, but no particular pathogen was responsible. Advancing age did not appear to be a protection against infection in these children, who had a mean age of death of 6 years, with 63% over 5 years of age at the time of death. Five children died of pneumonia, a common problem in children with Down's syndrome, and in two of these congenital heart disease contributed to cause of death. The immune system has been extensively studied in patients with Down's syndrome with conflicting results, but abnormalities of the thymus,'6 T cell and subsets activity,19 and neutrophil function'6 have been well documented. Impaired immune surveillance may in part account for the increased incidence of haematological malignancies seen with these children. The children with Down's syndrome and acute myeloid leukaemia presented at a younger age than controls; this has been reported before'3 and there was a higher percentage of megakaryocytic leukaemia'7 and erythroleukaemia. As reported in the paper of Robison et al there was no significant difference in survival from children without Down's syndrome.'3 The use of doxorubicin or other cardiotoxic drugs must be monitored with care even in children without congenital heart disease-as shown by our two patients who suffered irreversible cardiomyopathy, one of whom had a normal echocardiogram.
We conclude that patients with Down's syndrome and acute leukaemia have a poor prognosis, probably not because their disease is more aggressive, but because of associated congenital abnormalities, poor tolerance of infection, and possible altered drug metabolism that makes appropriate treatment difficult. Modification of cytotoxic treatment to prevent treatment related deaths, however, is likely to lead to poor response to treatment so that the only effective approach to treatment is to give standard protocols with full supportive care and an aggressive policy for detection and treatment of infections.
